Background {#Sec1}
==========

Cataract is defined as partial or complete loss of transparency of the crystalline lens and is considered the primary cause of vision loss worldwide \[[@CR1]\]. The high prevalence and incidence of cataract have resulted in a large public health burden. Although the actual mechanism of cataract development remains unclear, several risk factors have been established, including age \[[@CR2]\], corticosteroid use \[[@CR3]\], hypertension \[[@CR4]\], smoking \[[@CR5]\], and so on.

Recently, emerging epidemiological studies have focused on the risk of cataract formation of antidepressants. Two population-based studies from Canada \[[@CR6]\] and the United States \[[@CR7]\] suggested a significant positive association between the use of selective serotonin reuptake inhibitors (SSRIs) and the incidence of cataract. Beaver Dam Eye study showed a tendency toward an increased risk of cataract in users of amitriptyline, a tricyclic antidepressant (TCA) \[[@CR8]\]. On the other hand, Becker et al. \[[@CR9]\] failed to find a positive relationship between SSRIs and cataract risk using the UK-based Clinical Practice Research Datalink (CPRD).

Given the inconsistency and conflict of the existing literature and the insufficient statistical power of individual studies, we performed the present meta-analysis based on all eligible epidemiological studies that provided data on the association of antidepressants use with cataract risk.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

We performed this meta-analysis in accordance with the Meta-Analysis of Observational Studies in Epidemiology guidelines \[[@CR10]\]. A systematic literature search was carried out in PubMed and Web of Science databases through June 2017 by using the following search strategy: ("antidepressant" or "depression" or "selective serotonin reuptake inhibitor" or "SSRI" or "monoaminoxidase inhibitor" or "MAOI" or "tricyclic antidepressant" or "TCA" or "serotonin noradrenalin reuptake inhibitor" or "SNRI" or "serotonin antagonist and reuptake inhibitor" or "SARI" or "norepinephrine dopamine reuptake inhibitor" or "NDRI" or "norepinephrine reuptake inhibitor" or "NRI" or "noradrenergic and specific serotonergic antidepressant" or "NaSSA") and "Cataract", with no restrictions. Cited references of the retrieved articles and reviews were also checked.

Study selection {#Sec4}
---------------

Studies included in this meta-analysis met the following criteria: 1) had cohort, nested case-control or case-control study design; 2) the exposure of interest was antidepressants use, including SSRIs, TCAs, serotonin noradrenalin reuptake inhibitors (SNRIs), and so on; 3) the endpoint of interest was cataract incidence; and 4) the risk estimate and the corresponding 95% confidence interval (CI) were reported. If multiple studies used the same population, we included the study with the largest sample size.

Data extraction and quality assessment {#Sec5}
--------------------------------------

We extracted the following data using a standardized data-collection form: last name of the first author, publication year, study region, number of cases and controls, method of exposure and endpoint assessment, types of antidepressants, risk estimates from the most fully adjusted model and the corresponding 95% CIs, matched or adjusted potential confounders.

We assessed the quality of individual studies using Newcastle-Ottawa Scale (NOS), a 9-star system which consists of three dimensions: selection (four items), comparability (one item), and exposure/outcome (three items) (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>). Two authors (QD and YF) independently performed the literature search, study selection, data extraction, and quality assessment. Any disagreements were resolved by consensus.

Statistical analysis {#Sec6}
--------------------

A DerSimonian and Laird random-effects model \[[@CR11]\], which considered both within- and between-study variation, was used to calculate the combined estimate of effect size. For studies that separately provided estimated risk estimates for a number of categories of exposure compared with a single reference category, we combined these risk estimates within each study using the method reported by Hamling et al.'s study \[[@CR12]\]. Homogeneity across included studies was tested by *Q* statistics at the *P* \< 0.10 level of significance \[[@CR13]\]. The *I*^*2*^ score, a quantitative measure of inconsistency across studies, was also calculated \[[@CR13]\]. Potential publication bias was assessed by a visual funnel plot \[[@CR14]\]. All analyses were performed by using STATA version 10.0 (StataCorp, College Station, TX). A *P* value \< 0.05 was considered statistically significant, except where otherwise specified.

Results {#Sec7}
=======

Literature search and study characteristics {#Sec8}
-------------------------------------------

A flow chart showing the study selection process in detail is presented in Fig. [1](#Fig1){ref-type="fig"}. Seven studies \[[@CR6]--[@CR9], [@CR15]--[@CR17]\] were finally included in this meta-analysis. Of these, five studies were performed in North America, one in Europe, and one in Asia. All individual studies were case-control studies, of which four were nested case-control studies. Results for SSRIs were presented in six of these studies, four for SNRIs, and three for TCAs. These studies were published between 2001 and 2017. Information on exposure and endpoint were mainly collected from medical records. The NOS scores ranged from six to eight, with a mean value of 6.7. The main characteristics of all included studies have been summarized in Table [1](#Tab1){ref-type="table"}.Fig. 1Flow chart of study selectionTable 1Main characteristics of the studies included in this meta-analysisAuthorYearRegionDesignDrug typeNo. of casesNo. of controlsExposure measurementOutcome ascertainmentNOSMatched or adjusted variablesBecker et al.2017United KingdomCase-controlSSRI, TCA, SNRI, and MAOI206,931206,931Computer records (CPRD)Computer records (CPRD)8Calendar time (same index date), age, sex, general practice, and number of years of active history in the CPRD before the index date, BMI, smoking, diabetes, hypertension, and systemic steroidsChou et al.2017TaiwanNested case-controlSSRI, TCA, and SNRI76516637Computer records (NHIRD)Computer records (NHIRD)8Age, sex, index date, patient's demographics, mental illness characteristics, propensity score derived from comorbid conditions, and concomitant medicationsErie et al.2014United StatesCase-controlSSRI60246024Medical recordsMedical records7Age, sex, and date of surgeryWise et al.2014United StatesNested case-controlSSRI45,065450,650Medical records (IMS LifeLink database)Medical records (IMS LifeLink database)6Age, time of cohort entry, and follow-up timePakzad-Vaezi et al.2013CanadaNested case-controlSSRI162,501650,004Medical records (British Columbia Ministry of Health)Medical records (British Columbia Ministry of Health)6Age, time of cohort entry, and follow-up timeEtminan et al.2010CanadaNested case-controlSSRI and SNRI18,784187,840Medical recordsMedical records6Age, cohort entry, gender, hypertension, antihypertensive, antidiabetics, statins, and all forms of corticosteroidsKlein et al.2001United StatesCase-controlTCA7162305Medical history questionnaireDiagnosed by an ophthalmologist6Age and gender*No.* number, *NOS* Newcastle-Ottawa Scale, *y* year, *SSRI* selective serotonin reuptake inhibitor, *TCA* tricyclic antidepressant, *SNRI* serotonin noradrenalin reuptake inhibitor, *MAOI* monoaminoxidase inhibitor, *NHIRD* National Health Insurance Research Database, *BMI* body mass index, *CPRD* Clinical Practice Research Datalink

Main analysis by antidepressant classifications {#Sec9}
-----------------------------------------------

The multivariable-adjusted odds ratios (ORs) for each study and the pooled ORs for the any exposure versus none of antidepressants are presented in Fig. [2](#Fig2){ref-type="fig"}. Overall, the combined ORs (95% CIs) of cataract for SSRIs, SNRIs, and TCAs were 1.12 (1.06--1.19), 1.13 (1.04--1.24), and 1.19 (1.11--1.28), respectively. Obvious heterogeneity was found across studies (*P* \< 0.001, *I*^*2*^ = 92.2% for SSRIs, *P* = 0.026, *I*^*2*^ = 67.5% for SNRIs, and *P* = 0.092, *I*^*2*^ = 58.0% for TCAs).Fig. 2Random-effects meta-analysis of studies that examined three types of antidepressants use may increase the risk of cataract. **a** SSRIs use; **b** SNRIs use; **c** TCAs use

Subgroup analyses by individual antidepressant drugs {#Sec10}
----------------------------------------------------

The results of subgroup analysis according to individual antidepressant drugs are presented in Fig. [3](#Fig3){ref-type="fig"}. For SSRIs antidepressant drugs, a significantly direct association with cataract incidence was observed for fluoxetine (RR 1.08, 95% CI 1.03--1.12) and fluvoxamine (RR 1.22, 95% CI 1.06--1.40). No evidence of association was found for the rest of SSRIs drugs. For SNRIs antidepressant drugs, the combined ORs (95% CIs) of cataract for any exposure versus none were 1.35 (0.77--2.36), 2.33 (0.94--5.74), and 1.30 (1.18--1.43) for duloxetine, milnacipran, and venlafaxine, respectively.Fig. 3Subgroup analyses by individual antidepressant drugs

Publication bias {#Sec11}
----------------

As only seven studies were included in the present meta-analysis, Begg's test \[[@CR18]\] and Egger's test \[[@CR14]\] were not eligible for publication bias analysis. Hence we adopted a visual funnel plot to qualitatively assess the publication bias. As shown in Fig. [4](#Fig4){ref-type="fig"}, a certain degree of asymmetry was observed, which indicated slight publication bias.Fig. 4A visual funnel plot to qualitatively assess the publication bias

Discussion {#Sec12}
==========

This meta-analysis of seven eligible studies involving 447,672 cases and 1,510,391 controls supports a significant positive association of SSRIs, SNRIs and TCAs use with risk of cataract. To the best of our knowledge, this is the first systematic review and meta-analysis aimed to evaluate the relationship between antidepressants use and risk of cataract development.

Heterogeneity is often a concern in a meta-analysis. In the present study, obvious heterogeneity was observed among most analyses, which was partially explained by the following factors: study design was different. Although most included studies were performed in Western countries, population characteristics still varied in genetic and environmental background, antidepressants use, and matched or adjusted confounders.

Several mechanisms may be involved in the positive association of antidepressants use with cataract risk. In animal models, serotonin has been reported to play a crucial role in lens transparency \[[@CR19]\]. Elevated serotonin levels have been shown to lead to lens opacity in rats \[[@CR20]\]. Similarly, cataract and glaucoma patients also had increased levels of serotonin in the aqueous humor \[[@CR21]\]. In addition, serotonin 5-HT1A, 5-HT2A/2C, and 5-HT7 receptors have been identified in the crystalline lens, which participate in regulation of intraocular pressure (IOP) homeostasis \[[@CR22]\]. Increased IOP is able to contribute to glaucoma, which is a risk factor for cataract formation \[[@CR23]\]. TCAs use is reported to be related with photosensitivity to ultraviolet or sunlight. This latter exposure has been suggested to be associated with cortical cataract in Beaver Dam Eye Study \[[@CR24]\]. On the other hand, TCAs is able to inhibit norepinephrine uptake, which may also have cataractogenic properties \[[@CR25]\].

Our study had some important strengths. Considering individual studies had limited statistical power, this meta-analysis of seven studies involving a large number of cases and controls improved the power to detect a potential association and provided more robust estimates. Most of the original studies matched or adjusted a series of variables, which greatly reduced the likelihood of confounding bias.

Potential limitations of our study should be considered. First, the number of eligible studies was limited, especially in some subgroup analyses, which might influence the reliability of the results. Second, significant heterogeneity was observed among included studies, which might distort the conclusion of our study. Third, a certain degree of publication bias was observed. Gray literature (e.g., conference abstract) was difficult to find and studies with null results were less likely to be published. Finally, random misclassification of antidepressants might influence the results.

Conclusion {#Sec13}
==========

Use of antidepressants, including SSRIs, SNRIs and TCAs, is associated with an increased risk of cataract development. Considering the huge heterogeneity and limited included studies, further large well-designed prospective studies are warranted to confirm the preliminary findings of our study.
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